Dicarbonate | 214335-04-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机碳酸及其衍生物
• 英文名称: Dicarbonate
• 英文别名: carboxylato carbonate
• CAS: 214335-04-3
• 化学式: C2O5-2
• 分子量: 104.02
• InChiKey: ZFTFAPZRGNKQPU-UHFFFAOYSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  7
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  89.5
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-氨基-1-苯基丙烷-1-醇 、 Carbonochloridate 、 Dicarbonate 以to form an N-(3-hydroxy-3-phenylpropyl)urethane的产率得到N-(ethoxycarbonyl)-3-amino-1-phenyl-1-propanol
  参考文献：
  名称：

  US06025517

  摘要：

  公开号：

文献信息

• Compositions for labeling beta-amyloid plaques and neurofibrillary tangles
  申请人：——

  公开号：US20040072371A1

  公开（公告）日：2004-04-15

  Compositions useful for labeling &bgr;-amyloid plaques and neurofibrillary tangles are provided. The compositions comprises compounds of formula (I): 1 wherein R 1 is selected from the group consisting of —C(O)-alkyl, —C(O)-alkylenyl-R 4 , —C(O)O-alkyl, —C(O)O-alkylenyl-R 4 , —C═C(CN) 2 -alkyl, —C═C(CN) 2 -alkylenyl-R 4 , 2 wherein R 4 is a radical selected from the group consisting of alkyl, substituted alkyl, aryl and substituted aryl; R 5 is a radical selected from the group consisting of —NH 2 , —OH, —SH, —NH-alkyl, —NHR 4 , —NH-alkylenyl-R 4 , —O-alkyl, —O-alkylenyl-R 4 , —S-alkyl, and —S-alkylenyl-R 4 ; R 6 is a radical selected from the group consisting of —CN, —COOH, —C(O)O-alkyl, —C(O)O-alkylenyl-R 4 , —C(O)-alkyl, —C(O)-alkylenyl-R 4 , —C(O)-halogen, —C(O)NH-alkyl, —C(O)NH-alkylenyl-R 4 and —C(O)NH 2 ; R 7 is a radical selected from the group consisting of O, NH, and S; and R 8 is N, O or S; and R 2 is selected from the group consisting of alkyl and alkylenyl-R 10 and R 3 is alkylenyl-R 10 , wherein R 10 is selected from the group consisting of —OH, —OTs, halogen, spiperone, spiperone ketal, and spiperone-3-yl, or R 2 and R 3 together form a heterocyclic ring, optionally substituted with at least one radical selected from the group consisting of alkyl, alkoxy, OH, OTs, halogen, alkyl-R 10 , carbonyl, spiperone, spiperone ketal and spiperone-3-yl, and further wherein one or more of the hydrogen, halogen or carbon atoms are optionally replaced with a radiolabel.

  提供了用于标记&bgr;-淀粉样斑块和神经原纤维缠结的组合物。该组合物包括以下化合物(I)：1其中R1选自由—C(O)-烷基，—C(O)-烷基烯基-R4，—C(O)O-烷基，—C(O)O-烷基烯基-R4，—C═C(CN)2-烷基，—C═C(CN)2-烷基烯基-R4，2其中R4选自烷基，取代烷基，芳基和取代芳基中的一种基团；R5选自—NH2，—OH，—SH，—NH-烷基，—NHR4，—NH-烷基烯基-R4，—O-烷基，—O-烷基烯基-R4，—S-烷基和—S-烷基烯基-R4中的一种基团；R6选自—CN，—COOH，—C(O)O-烷基，—C(O)O-烷基烯基-R4，—C(O)-烷基，—C(O)-烷基烯基-R4，—C(O)-卤素，—C(O)NH-烷基，—C(O)NH-烷基烯基-R4和—C(O)NH2中的一种基团；R7选自O，NH和S；R8为N，O或S；R2选自烷基和烷基烯基-R10，R3为烷基烯基-R10，其中R10选自—OH，—OTs，卤素，斯皮罗隆，斯皮罗隆酮，和斯皮罗隆-3-基，或R2和R3一起形成一个杂环环，可选地取代至少一个选自烷基，烷氧基，OH，OTs，卤素，烷基-R10，羰基，斯皮罗隆，斯皮罗隆酮和斯皮罗隆-3-基的基团，进一步其中一个或多个氢，卤素或碳原子可选择用放射性标记取代。
• Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
  申请人：Sui Zhihua

  公开号：US20050113402A1

  公开（公告）日：2005-05-26

  The invention relates to novel pyrrolopyridinone derivatives of the formula (I) or (II): pharmaceutical compositions containing the compounds and their use for the treatment of sexual dysfunction.

  本发明涉及化合物式（I）或（II）的新型吡咯吡啶酮衍生物：以及含有这些化合物的药物组合物，以及它们用于治疗性功能障碍的用途。
• Method for preparation of sphingoid bases
  申请人：The United States of America represented by the Department of Health and

  公开号：US05430169A1

  公开（公告）日：1995-07-04

  The present invention provides a series of non-toxic compounds which function to inhibit the activity of S-1-P aldolase in respect to its cleavage of S-1-P. These inhibitors are described by the compounds of formula I ##STR1## wherein R is a radical containing 1 to 15 carbon atoms, a halogen, or hydrocarbon, R' is an organic radical or hydrogen, and R" is --NH.sub.3.sup.+ or --NH--NH .sup.+, with the proviso that, when R is CH.sub.3 (CH).sub.12 (CH.dbd.CH) and R' is hydrogen, R" is --NH--NH.sub.3.sup.+. A method for preparing such compounds, which may generally be described as 1-phosphate derivatives of compounds which include a 2-amino-1,3-alcohol radical is also disclosed.

  本发明提供了一系列无毒化合物，其在抑制S-1-P醛缩酶对S-1-P的裂解活性方面发挥作用。这些抑制剂由式I的化合物描述：##STR1##其中R是含有1至15个碳原子的基团，卤素或烃基，R'是有机基团或氢，R"是--NH.sub.3.sup.+或--NH--NH .sup.+，但当R为CH.sub.3(CH).sub.12(CH.dbd.CH)且R'为氢时，R"为--NH--NH.sub.3.sup.+。还公开了一种制备这种化合物的方法，该方法通常可描述为包括2-氨基-1,3-醇基团的化合物的1-磷酸酯衍生物。
• Fluorinated diaminobutane derivatives
  申请人：Merrell Toraude et Compagnie

  公开号：US04435425A1

  公开（公告）日：1984-03-06

  Fluorinated diaminobutane compounds in vivo are inhibitors of gamma-aminobutyric acid transaminase and have the following formula: ##STR1## wherein: R.sub.1 represents hydrogen, C.sub.1 -C.sub.6 alkyl, or phenyl-(C.sub.1 -C.sub.4 alkyl); R.sub.2 represents hydrogen, C.sub.1 -C.sub.6 alkyl, phenyl-(C.sub.1 -C.sub.4 alkyl), or R.sub.4, where R.sub.4 is as defined below; R.sub.3 represents hydrogen, or, except when R.sub.2 represents R.sub.4, R.sub.4, where R.sub.4 is as defined below; each R.sub.4, independently, represents C.sub.2 -C.sub.5 alkylcarbonyl, phenylcarbonyl, phenyl-(C.sub.1 -C.sub.4 alkyl) carbonyl, or an aminocarboxylic acid residue derived by removal of an hydroxy group from the carboxy moiety of an L-aminocarboxylic acid; and p represents 1 or 2, and pharmaceutically acceptable acid addition salts thereof.

  体内的氟代二氨基丁烷化合物是γ-氨基丁酸转氨酶的抑制剂，具有以下式子：##STR1## 其中：R.sub.1代表氢，C.sub.1-C.sub.6烷基或苯基-(C.sub.1-C.sub.4烷基)；R.sub.2代表氢，C.sub.1-C.sub.6烷基，苯基-(C.sub.1-C.sub.4烷基)或R.sub.4，其中R.sub.4的定义如下；R.sub.3代表氢，或者除非R.sub.2代表R.sub.4，否则为R.sub.4，其中R.sub.4的定义如下；每个独立的R.sub.4代表C.sub.2-C.sub.5烷基羰基，苯基羰基，苯基-(C.sub.1-C.sub.4烷基)羰基，或通过从L-氨基羧酸的羧基中去除羟基所得的氨基羧酸残基；p代表1或2，以及其药学上可接受的酸加成盐。
• Methods for labeling beta-amyloid plaques and neurofibrillary tangles
  申请人：The Regents of the University of California

  公开号：US20020022002A1

  公开（公告）日：2002-02-21

  A method for labeling &bgr;-amyloid plaques and neurofibrillary tangles in vivo and in vitro, comprises contacting a compound of formula (I): 1 with mammalian tissue. In formula (I), R 1 is selected from the group consisting of —C(O)-alkyl, —C(O)-alkylenyl-R 4 , —C(O)O-alkyl, —C(O)O-alkylenyl-R 4 , —C═C(CN) 2 -alkyl, —C═C(CN) 2 -alkylenyl-R 4 , 2 R 4 is a radical selected from the group consisting of alkyl, substituted alkyl, aryl and substituted aryl; R 5 is a radical selected from the group consisting of —NH 2 , —OH, —SH, —NH-alkyl, —NHR 4 , —NH-alkylenyl-R 4 , —O-alkyl, —O-alkylenyl-R 4 , —S-alkyl, and —S-alkylenyl-R 4 ; R 6 is a radical selected from the group consisting of —CN, —COOH, —C(O)O-alkyl, —C(O)O-alkylenyl-R 4 , —C(O)-alkyl, —C(O)-alkylenyl-R 4 , —C(O)-halogen, —C(O)NH 2 , —C(O)NH-alkyl, —C(O)NH-alkylenyl-R 4 ; R 7 is a radical selected from the group consisting of O, NH, and S; and R 8 is N, O or S. R 2 and R 3 are each independently selected from the group consisting of alkyl and alkylenyl-R 10 , wherein R 10 is selected from the group consisting of —OH, —OTs, halogen, spiperone, spiperone ketal and spiperone-3-yl. Alternatively, R 2 and R 3 together form a heterocyclic ring, optionally substituted with at least one radical selected from the group consisting of alkyl, alkoxy, OH, OTs, halogen, alkylenyl-R 10 , carbonyl, spiperone, spiperone ketal and spiperone-3-yl. In the compounds of formula (I), one or more of the hydrogen, halogen or carbon atoms can, optionally, be replaced with a radiolabel.

  一种用于体内和体外标记β淀粉样斑块和神经原纤维缠结的方法，包括将式(I)的化合物1与哺乳动物组织接触。在式(I)中，R1选自由以下组成的群体：—C(O)-烷基，—C(O)-烷基亚烷基-R4，—C(O)O-烷基，—C(O)O-烷基亚烷基-R4，—C═C(CN)2-烷基，—C═C(CN)2-烷基亚烷基-R4，2R4选自由以下组成的基团：烷基，取代烷基，芳基和取代芳基；R5选自由以下组成的基团：—NH2，—OH，—SH，—NH-烷基，—NHR4，—NH-烷基亚烷基-R4，—O-烷基，—O-烷基亚烷基-R4，—S-烷基和—S-烷基亚烷基-R4；R6选自由以下组成的基团：—CN，—COOH，—C(O)O-烷基，—C(O)O-烷基亚烷基-R4，—C(O)-烷基，—C(O)-烷基亚烷基-R4，—C(O)-卤素，—C(O)NH2，—C(O)NH-烷基，—C(O)NH-烷基亚烷基-R4；R7选自由以下组成的基团：O，NH和S；R8是N，O或S。R2和R3各自独立地选自由以下组成的群体：烷基和亚烷基-R10，其中R10选自由以下组成的群体：—OH，—OTs，卤素，spiperone，spiperone ketal和spiperone-3-yl。或者，R2和R3一起形成一个杂环，可选地用以下至少一个基团取代：烷基，烷氧基，OH，OTs，卤素，亚烷基-R10，羰基，spiperone，spiperone ketal和spiperone-3-yl。在式(I)的化合物中，一个或多个氢、卤素或碳原子可以选择性地被放射性标记取代。